Eduardo Longoria

Eduardo Longoria

BMS and Hengrui Pharma sign a $15.2 billion alliance & Boehringer secures a preclinical antibody from Immunitas for $478 million

BMS and Hengrui Pharma sign a $15.2 billion alliance & Boehringer secures a preclinical antibody from Immunitas for $478 million

Joachim Eeckhout, +1
Cellular Intelligence gives Novo's Parkinson ́s program a second life & Inhibrx reports encouraging phase 2 data

Cellular Intelligence gives Novo's Parkinson ́s program a second life & Inhibrx reports encouraging phase 2 data

Joachim Eeckhout, +1
Odyssey Therapeutics goes public with $279 million IPO & Roche acquires PathAI for up to $1.05 billion

Odyssey Therapeutics goes public with $279 million IPO & Roche acquires PathAI for up to $1.05 billion

Joachim Eeckhout, +1
Angelini Pharma is buying Catalyst for $4.1 billion & InflaRx secures $150 million for its pivot

Angelini Pharma is buying Catalyst for $4.1 billion & InflaRx secures $150 million for its pivot

Joachim Eeckhout, +1
Bayer purchases eye therapy specialist Perfuse for $2.45B & GSK signs $1B deal in China to target stubborn belly fat

Bayer purchases eye therapy specialist Perfuse for $2.45B & GSK signs $1B deal in China to target stubborn belly fat

Joachim Eeckhout, +1
Cytospire raises $83M to advance its gamma-delta T-cell engagers & Madrigal deepens its MASH pipeline with $1B Arrowhead deal

Cytospire raises $83M to advance its gamma-delta T-cell engagers & Madrigal deepens its MASH pipeline with $1B Arrowhead deal

Joachim Eeckhout, +1
UCB bets $2.2B on Candid's T-cell engagers & Windward raises $165M to challenge asthma leaders

UCB bets $2.2B on Candid's T-cell engagers & Windward raises $165M to challenge asthma leaders

Joachim Eeckhout, +1
Three biotech raise $856M in IPOs & FDA clears Arvinas’ first-in-class PROTAC breast cancer drug

Three biotech raise $856M in IPOs & FDA clears Arvinas’ first-in-class PROTAC breast cancer drug

Joachim Eeckhout, +1
Chiesi expands rare disease footprint with $1.9B KalVista acquisition & Teva bets $700M on late-stage Tourette drug

Chiesi expands rare disease footprint with $1.9B KalVista acquisition & Teva bets $700M on late-stage Tourette drug

Joachim Eeckhout, +1
Coultreon raises $125M to rescue a Galapagos drug & AbbVie signs a $1.45B KRAS deal

Coultreon raises $125M to rescue a Galapagos drug & AbbVie signs a $1.45B KRAS deal

Joachim Eeckhout, +1